Reloxaliase is a crystalline formulation of oxalate decarboxylase derived from Bacillus Subtilis. Reloxaliase is under investigation in clinical trial NCT03456830 (Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria).
Reloxaliase is a crystalline formulation of oxalate decarboxylase derived from Bacillus Subtilis. Reloxaliase is under investigation in clinical trial NCT03456830 (Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria).
No indication information available.
No associated conditions information available.
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2019/02/20 | Phase 3 | Terminated | Allena Pharmaceuticals | ||
2018/03/07 | Phase 3 | Completed | Allena Pharmaceuticals | ||
2018/01/05 | Phase 2 | Completed | Allena Pharmaceuticals | ||
2015/09/11 | Phase 2 | Completed | Allena Pharmaceuticals | ||
2014/11/13 | Phase 2 | Completed | Allena Pharmaceuticals |
Product Name | Manufacturer | Route | Strength | Approved | NDC Code |
---|
No FDA products found for this drug
Medicine Name | EMA Number | Auth. Holder | Country | Drug Type | Status | Issued | Opinion | Revision |
---|
No EMA products found for this drug
Product Name | Manufacturer | Dosage Form | Strength | Approved | Approval No. | Online |
---|
No Singapore products found for this drug
Product Name | Approval No. | Manufacturer | Dosage Form | Trade Name | Strength | Type | Status | Date | Import |
---|
No China products found for this drug
Product Name | ARTG ID | Sponsor | Status | Reg. Date | Ingredient |
---|
No Australia products found for this drug